ConductScience.org, home

Paper37101392

Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.

Xu R and 4 others. CPT Pharmacometrics Syst Pharmacol, 2023. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution. Papers, record 37101392. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37101392

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
PubMed
Journal
CPT Pharmacometrics Syst Pharmacol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
2.03
iCite
Revised in PubMed
2024-06-07
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xu RRuijuan
2Liu WWenyuan
3Ge WWeihong
4He HHua
5Jiang QQing

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ThiazolesMajor topic
Renal InsufficiencyMajor topic
Adult
Humans
Pyridines
Drug Interactions
Anticoagulants
Models, Biological
Computer Simulation

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in38845389Correction to "Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution".https://conductscience.org/library/papers/38845389

Source PubMed

Download CSV of comments and corrections

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136002079The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans.Pharmacol Ther2022https://conductscience.org/library/papers/36002079PubMed
231506301Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.Drug Metab Dispos2019https://conductscience.org/library/papers/31506301PubMed
327647273Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.J Pharmacokinet Pharmacodyn2016https://conductscience.org/library/papers/27647273PubMed
425186833Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.Clin Drug Investig2014https://conductscience.org/library/papers/25186833PubMed
535745692Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.Pharmaceutics2022https://conductscience.org/library/papers/35745692PubMed
627897269An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.Pharmacogenomics J2018https://conductscience.org/library/papers/27897269PubMed
735579824Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.Clin Pharmacokinet2022https://conductscience.org/library/papers/35579824PubMed
829728318Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician.Am J Kidney Dis2018https://conductscience.org/library/papers/29728318PubMed
932987693Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.Int J Mol Sci2020https://conductscience.org/library/papers/32987693PubMed
1031420941
Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.
CPT Pharmacometrics Syst Pharmacol2019https://conductscience.org/library/papers/31420941PubMed
1120135207Model analysis of the concentration-dependent permeability of P-gp substrates.Pharm Res2010https://conductscience.org/library/papers/20135207PubMed
1237101392Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37101392PubMed
1333545293Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model.Int J Pharm2021https://conductscience.org/library/papers/33545293PubMed
1432504376Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.Drugs2020https://conductscience.org/library/papers/32504376PubMed
1528990182Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Clin Pharmacol Ther2018https://conductscience.org/library/papers/28990182PubMed
1622936313Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.Drug Metab Dispos2012https://conductscience.org/library/papers/22936313PubMed
1728599065The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.Clin Pharmacol Ther2017https://conductscience.org/library/papers/28599065PubMed
1829996058Assessment of Transporter-Mediated and Passive Hepatic Uptake Clearance Using Rifamycin-SV as a Pan-Inhibitor of Active Uptake.Mol Pharm2018https://conductscience.org/library/papers/29996058PubMed
1911062690Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats.Anticancer Res2000https://conductscience.org/library/papers/11062690PubMed
2015762770Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.Clin Pharmacokinet2005https://conductscience.org/library/papers/15762770PubMed

See all 36 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42771268Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations.J Pharmacokinet Pharmacodyn2026https://conductscience.org/library/papers/42771268PubMed
42652049Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism.Biomedicines2026https://conductscience.org/library/papers/42652049PubMed
42484904
Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children.
Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42484904PubMed
41332151Characterizing Apixaban Pharmacokinetics Through Physiologically-Based Pharmacokinetic Modeling: Critical Role of Biliary Secretion and Enterohepatic Circulation in Humans.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/41332151PubMed
41276277Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.Br J Clin Pharmacol2026https://conductscience.org/library/papers/41276277PubMed
40425954
Risk Assessment for Biopharmaceutics Classification System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling.
AAPS J2025https://conductscience.org/library/papers/40425954PubMed
39468637Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report.J Pharm Health Care Sci2024https://conductscience.org/library/papers/39468637PubMed
37101392Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37101392PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37101392

GET https://conductscience.org/api/papers/v1/37101392/references?page=2